Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

References

• ShakespeareWThe Tragedy of MacbethAct 1, scene 4, line 13.
   Google Scholar
• LewisMBBowlerPJBotulinum toxin cosmetic therapy correlates with a more positive moodJ Cosmet Dermatol200981242619250162
   PubMed Web of Science ®Google Scholar
• EkmanPFacial expression and emotionAm Psychol19934843843928512154
   PubMed Web of Science ®Google Scholar
• HeckmannMTeichmannBSchroderUSprengelmeyerRCeballos-BaumannAOPharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fearJ Am Acad Dermatol200349221321612894067
   PubMed Web of Science ®Google Scholar
• StrackFNeumannRFurrowing the brow may undermine perceived fame: the role of facial feedback in judgments of celebrityPers Soc Psychol Bull2000267762768
   Web of Science ®Google Scholar
• DimbergUFacial reactions to fear-relevant and fear-irrelevant stimuliBiol Psychol19862321531613790652
   PubMed Web of Science ®Google Scholar
• HoffmannKHahnCLeisingDBecharaFGGeorgasDTomiNS“Emotional expressivity” after botulinumtoxin anti-wrinkle treatment. [poster]21st Annual World Congress of DermatologySeptember 30–October 5, 2007Buenos Aires, Argentina
   Google Scholar
• HoffmannKHahnCLeisingDBecharaFGGeorgasDTomiNS“Interpersonal attraction” and “well-being” after botulinumtoxin anti-wrinkle treatment. [poster]21st Annual World Congress of DermatologySeptember 30–October 5, 2007Buenos Aires, Argentina
   Google Scholar
• Mac PhersonSSelf-esteem and cosmetic enhancementPlast Surg Nurs200525152015785350
   PubMedGoogle Scholar
• StrackFMartinLLStepperSInhibiting and facilitating conditions of the human smile: a nonobtrusive test of the facial feedback hypothesisJ Pers Soc Psychol19885457687773379579
   PubMed Web of Science ®Google Scholar
• VanSwearingenJMCohnJFBajaj-LuthraASpecific impairment of smiling increases the severity of depressive symptoms in patients with facial neuromuscular disordersAesthetic Plast Surg199923641642310629298
   PubMed Web of Science ®Google Scholar
• FinziEWassermanETreatment of depression with botulinum toxin A: a case seriesDermatol Surg200632564564916706759
   PubMed Web of Science ®Google Scholar
• LeffellDJForewordKaminerMSDoverJSArndtKAAtlas of Cosmetic Surgery1st edPhiladelphia, PaW. B. Saunders Company2001ixx
   Google Scholar
• CarruthersJDACarruthersJATreatment of glabellar frown lines with C. botulinum-A exotoxinJ Dermatol Surg Oncol199218117211740562
   PubMedGoogle Scholar
• Allergan IncBotox Cosmetic: About Safetyhttp://www.botoxcosmetic.com/botox_safety/fda_approval.aspx Accessed September 1, 2009.
   Google Scholar
• US Food and Drug AdministrationFDA Requires Boxed Warning for All Botulinum Toxin Productshttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149574.htm Accessed August 25, 2009.
   Google Scholar
• FlynnTCClarkREBotulinum toxin type B (Myobloc) versus botulinum toxin type A (Botox) frontalis study: rate of onset and radius of diffusionDermatol Surg200329551952212752521
   PubMed Web of Science ®Google Scholar
• BaumannLSlezingerAVujevichJA double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow’s feet: a double-blinded, placebo-controlled trialDermatol Surg200329550851512752519
   PubMed Web of Science ®Google Scholar
• GlogauRGTopically applied botulinum toxin type a for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled studyDermatol Surg2007331 Spec NoS76S8017241418
   PubMed Web of Science ®Google Scholar
• AokiKRGuyerBBotulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actionsEur J Neurol20018Suppl 5212911851731
   PubMed Web of Science ®Google Scholar
• AokiKRBotulinum toxin: a successful therapeutic proteinCurr Med Chem200411233085309215579002
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJBotulinum toxin products overviewSkin Therapy Lett20081361418806905
   PubMedGoogle Scholar
• BaumannLBlackLBotulinum toxin type B (Myobloc)Dermatol Surg200329549650012752517
   PubMed Web of Science ®Google Scholar
• SadickNSProspective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinklesDermatol Surg200329550150712752518
   PubMed Web of Science ®Google Scholar
• RamirezALReeckJMaasCSBotulinum toxin type B (MyoBloc) in the management of hyperkinetic facial linesOtolaryngol Head Neck Surg2002126545946712075218
   PubMed Web of Science ®Google Scholar
• KleinAWCarruthersAFagienSLoweNJComparisons among botulinum toxins: an evidence-based reviewPlast Reconstr Surg20081216413e422e
   Google Scholar
• AokiKRPharmacology and immunology of botulinum neurotoxinsInt Ophthalmol Clin2005453253715970764
   PubMedGoogle Scholar
• FlynnTCBotulinum toxin: examining duration of effect in facial aestheticAm J Clin Dermatol2009
   Web of Science ®Google Scholar
• FagienSCarruthersJDAA comprehensive review of patient-reported satisfaction with botulinum toxin type A for aesthetic proceduresPlast Reconstr Surg200812261915192519050545
   PubMed Web of Science ®Google Scholar
• De BoulleKLVBotulinum neurotoxin type A in facial aestheticsExpert Opin Pharmacother2007881059107217516871
   PubMed Web of Science ®Google Scholar
• DollyJOAokiKRThe structure and mode of action of different botulinum toxinsEur J Neurol200613Suppl 41917112344
   PubMed Web of Science ®Google Scholar
• FrevertJXeomin is free from complexing proteinsToxicon200915
   Web of Science ®Google Scholar
• HuntTClarkeKPotency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type AClin Neuropharmacol2009321283118978494
   PubMed Web of Science ®Google Scholar
• JostWHKohlABrinkmannSComesGEfficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteersJ Neural Transm2005112790591315526142
   PubMed Web of Science ®Google Scholar
• RosalesRLBigalkeHDresslerDPharmacology of botulinum toxin: differences between type A preparationsEur J Neurol200613Suppl 121016417591
   PubMed Web of Science ®Google Scholar
• AokiKRSatoriusAArdilaCBrownMNicholsonGFrancisJPharmacology of BOTOX, Dysport, Myobloc and BTX-A in animal models of efficacy and safety[abstract] International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus ToxinsJune 23–25, 2005Denver, CO, USA
   Google Scholar
• Trindade De AlmeidaAde BoulleKDiffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applicationsJ Cosmet Laser Ther20079Suppl 1172217885882
   PubMedGoogle Scholar
• HexselDDal’FornoTHexselCdo PradoDZLimaMMA randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type ADermatol Surg2008341525918053050
   PubMed Web of Science ®Google Scholar
• CliffSHJudodihardjoHEltringhamEDifferent formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized studyJ Cosmet Dermatol200871505418254812
   PubMedGoogle Scholar
• HexselDRodriguesTCSoirefmannMEfficacy and field of effectiveness of two commercial preparations of botulinum toxin type A in the frontalis muscles – a double-blind, randomized and controlled study[abstract] European Masters of Anti Aging Annual ConferenceOctober 2–3, 2009Paris, France
   Google Scholar
• CarruthersACarruthersJLoweNJfor the BOTOX® Glabellar Lines I and II Study GroupsOne-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar linesJ Clin Res20047120
   Google Scholar
• Dysport [package insert]Brisbane, CAMedicis Aesthetics Inc.2009
   Google Scholar
• US Food and Drug AdministrationInformation for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc)http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm Accessed August 25, 2009.
   Google Scholar
• US Food and Drug AdministrationFollow-up to the February 8, 2008, Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm143819.htm Accessed September 14, 2009.
   Google Scholar
• Botox Cosmetic [package insert]Irvine, CAAllergan, Inc.2009
   Google Scholar
• BlitzerABinderWJAvivJEKeenMSBrinMFThe management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patientsArch Otolaryngol Head Neck Surg199712343893929109785
   PubMedGoogle Scholar
• WiestLGAn overview of the cosmetic treatment of facial muscles with a new botulinum toxinActa Dermatovenerol Croat2009171485319386215
   PubMed Web of Science ®Google Scholar
• AscherBZakineBKestemontPBaspeyrasMBougaraASantiniJA multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJ Am Acad Dermatol200451222323315280841
   PubMed Web of Science ®Google Scholar
• MonheitGCarruthersABrandtFRandRA randomized, double-blind, placebo-controlled study of botulinum toxin type a for the treatment of glabellar lines: determination of optimal doseDermatol Surg2007331 Spec NoS51S5917241415
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJLong-term safety review of subjects treated with botulinum toxin type A for cosmetic use. [poster]Proceedings of the 13th Congress of the European Academy of Dermatology and VenereologyNovember 17–21, 2004Florence, Italy
   Google Scholar
• KawashimaMHariiKAn open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjectsInt J Dermatol200948776877619490208
   PubMed Web of Science ®Google Scholar
• RzanyBDill-MüllerDGrablowitzDHeckmannMCairdDRepeated botulinum toxin a injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patientsDermatol Surg2007331 Spec NoS18S2517241409
   PubMed Web of Science ®Google Scholar
• MonheitGDCohenJLReloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: Interim analysis from an open-label extension studyJ Am Acad Dermatol200961342142519577326
   PubMed Web of Science ®Google Scholar
• MoyRMaasCMonheitGHuberBfor the Reloxin Investigational GroupLong-term safety and efficacy of a new botulinum toxin type A in treating glabellar linesArch Facial Plast Surg2009112778319289677
   PubMedGoogle Scholar
• BrinMFBoodhooTIPogodaJMSafety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participantsJ Am Acad Dermatol200961696197019744746
   PubMed Web of Science ®Google Scholar
• BrandtFSwansonNBaumannLHuberBRandomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safetyDermatol Surg2009351893190119549186
   PubMed Web of Science ®Google Scholar
• HariiKKawashimaMA double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjectsAesthetic Plast Surg200832572473018663516
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJProspective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytidsDermatol Surg200531101297130316188182
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJSaidSDose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in femalesDermatol Surg200531441442215871316
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJCohenJDilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?Dermatol Surg2007331 Spec NoS97S10417241422
   PubMed Web of Science ®Google Scholar
• GrimesPEShabazzDA four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VIDermatol Surg200935342943519250310
   PubMed Web of Science ®Google Scholar
• RzanyBAscherBFratilaAMonheitGDTalaricoSSterryWfor the GLADYS Study GroupEfficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead regionArch Dermatol2006142332032616549707
   PubMedGoogle Scholar
• KaneMABrandtFRohrichRJNarinsRSMonheitGDHuberMBRelovin Investigational Group. Evaluation of variable-dose treatment with a new US botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled studyPlast Reconstr Surg200912451619162919584772
   PubMed Web of Science ®Google Scholar
• LowePPatnaikRLoweNComparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized studyJ Am Acad Dermatol200655697598017097394
   PubMed Web of Science ®Google Scholar
• AscherBZakineBKestemontPBotulinum toxin A in the treatment of glabellar lines: scheduling the next injectionAesth Surg J200525365375
   PubMedGoogle Scholar
• CoxSEFinnJCStetlerLMackowiakJKowalskiJWDevelopment of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A-treated patientsDermatol Surg200329544444912752509
   PubMed Web of Science ®Google Scholar
• StotlandMAKowalskiJWRayBBPatient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label studyPlast Reconstr Surg200712051386139317898617
   PubMed Web of Science ®Google Scholar
• BeerKRComparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytidsDermatol Surg200632218419216442037
   PubMed Web of Science ®Google Scholar
• GrimesPEA four-month randomized, double-masked evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VIPoster presented at: the 62nd Annual Meeting of the American Academy of DermatologyFebruary 6–11, 2004Washington, DC
   Google Scholar
• EllisDAFChiPLTanAKWFacial rejuvenation with botulinumDermatol Nurs1997953293333659392763
   PubMedGoogle Scholar
• EdwardsCRTeelucksinghSGlycyrrhetinic acid and potentiation of hydrocortisone activity in skinLancet199033687103223231974017
   PubMed Web of Science ®Google Scholar
• De BoulleKPatient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytidsJ Cosmet Laser Ther2008102879218569261
   PubMed Web of Science ®Google Scholar
• DraycottSDabbsACognitive dissonance 1: An overview of the literature and its integration into theory and practice in clinical psychologyBr J Clin Psychol199837Pt 33413539784888
   PubMed Web of Science ®Google Scholar
• KowalskiJKozmaCReesePRSlatonTLeeJInitial development of a patient-completed questionnaire to assess outcomes of aesthetic treatment for hyperfunctional facial lines of the upper face[poster] American Academy of Dermatology Academy’s 2005 Annual MeetingJuly 20–24, 2005Chicago, Ill, USA
   Google Scholar
• CarruthersJCarruthersABotulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomesDermatol Surg2007331 Spec NoS10S1717241408
   PubMed Web of Science ®Google Scholar
• FagienSCoxSEFinnJCWerschlerWPKowalskiJWPatient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled studyDermatol Surg2007331 Spec NoS2S917241410
   PubMed Web of Science ®Google Scholar
• SommerBZschockeIBergfeldDSattlerGAugustinMSatisfaction of patients after treatment with botulinum toxin for dynamic facial linesDermatol Surg200329545646012752511
   PubMed Web of Science ®Google Scholar
• CarruthersJFagienSMatarassoSLthe Botox Consensus GroupConsensus recommendations on the use of botulinum toxin type A in facial aestheticsPlast Reconstr Surg2004114Suppl 61S22S15507786
   PubMed Web of Science ®Google Scholar
• CarruthersJDAGlogauRGBlitzerAthe Facial Aesthetics Consensus Group FacultyAdvances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies – consensus recommendationsPlast Reconstr Surg2008121Suppl 55S30S18449026
   PubMed Web of Science ®Google Scholar
• CarruthersJCarruthersAA prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-ADermatol Surg200329880280912859378
   PubMed Web of Science ®Google Scholar
• PatelMPTalmorMNolanWBBotox and collagen for glabellar furrows: advantages of combination therapyAnn Plast Surg200452544244715096921
   PubMed Web of Science ®Google Scholar
• KhouryJGSalujaRGoldmanMPThe effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face studyDermatol Surg200818
   Google Scholar
• WestTBAlsterTSEffect of botulinum toxin type A on movement-associated rhytides following CO2 laser resurfacingDermatol Surg199925425926110417577
   PubMed Web of Science ®Google Scholar
• YamauchiPSLaskGLoweNJBotulinum toxin type A gives adjunctive benefit to periorbital laser resurfacingJ Cosmet Laser Ther20046314514815545098
   PubMedGoogle Scholar
• ZimblerMSHoldsJBKokoskaMSEffect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trialArch Facial Plast Surg20013316516911497500
   PubMedGoogle Scholar
• CarruthersJCarruthersAThe effect of full-face broadband light treatments alone and in combination with bilateral crow’s feet botulinum toxin type A chemodenervationDermatol Surg200430335536615008861
   PubMed Web of Science ®Google Scholar
• CarruthersJCarruthersAComplications of botulinum toxin type AFacial Plast Surg Clin North Am20071515154vi17317555
   PubMedGoogle Scholar
• KrishtulAWaldorfHABlitzerAComplications of cosmetic botulinum toxin therapyCarruthersACarruthersJProcedures in Cosmetic Dermatology Series: Botulinum ToxinPhiladelphia, PAWB Saunders Company2005
   Google Scholar
• American Society for Aesthetic Plastic SurgeryCosmetic Surgery National Data Bank: 2008 Statistics http://www.surgery.org/download/2008stats.pdf. Accessed March17, 2009
   Google Scholar
• TierneyEPHankeCWRecent trends in cosmetic and surgical procedure volumes in dermatologic surgeryDermatol Surg20093591324133319496792
   PubMed Web of Science ®Google Scholar